A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04047641

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:48.215666+00:00

Published At

2025-12-17T00:00:00+00:00

Record Updated At

2025-12-17

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Acute Myeloid Leukemia", "Blasts 20 Percent or More of Bone Marrow Nucleated Cells", "High Risk Myelodysplastic Syndrome", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent High Risk Myelodysplastic Syndrome", "Refractory Acute Myeloid Leukemia", "Refractory High Risk Myelodysplastic Syndrome"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2025-12-17"

protocolSection.identificationModule.nctId

"NCT04047641"

protocolSection.identificationModule.officialTitle

"A Combination of Cladribine, Idarubicin, Cytarabine (CLIA) and Quizartinib for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS))"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Blasts 20 Percent or More of Bone Marrow Nucleated Cells (protocolSection.conditionsModule.conditions)
• High Risk Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
• Recurrent Acute Biphenotypic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent High Risk Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
• Refractory Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Refractory High Risk Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.